4.1 Article

Interleukin-13 in asthma

Journal

CURRENT OPINION IN PULMONARY MEDICINE
Volume 9, Issue 1, Pages 21-27

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00063198-200301000-00004

Keywords

-

Funding

  1. NHLBI NIH HHS [R01 HL67736, P01 HL10342] Funding Source: Medline
  2. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067736, P01HL010342] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Some time ago, the Th2 cytokine, interleukin (IL)-13, was identified as a critical regulator of the allergic response. Initial studies in animal models of disease provided compelling evidence that IL-13, independent from other Th2 cytokines, was necessary and sufficient to induce all features of allergic asthma. This contention was supported in human disease when strong associations between IL-13 levels and genetic polymorphisms in the IL-13 gene and disease correlates were found. With the preponderance of evidence continuing to support the importance of IL-13 in allergic disorders, attention is now turned towards understanding the mechanisms by which this cytokine may mediate the pathophysiologic features of allergic disease. The emerging paradigm is that IL-13 induces features of the allergic response via its actions on epithelial and smooth muscle cells not through traditional effector pathways involving eosinophils and IgE-mediated events. In light of recent developments, this review will explore our current understanding of the role of IL-13 in the pathogenesis of allergy and asthma with a particular focus on new insights into the mechanisms by which IL-13 induces the features of asthma. (C) 2003 Lippincott Williams Wilkins, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available